NTRK1 and cancer: SHP2 has recently been validated as a viable target for cancer therapy,3 and there is an increasing focus on identifying SHP2 inhibitors as potential chemotherapeutics.1,4,5 From these investigations, SHP099 has emerged as a promising drug candidate.6–8 An allosteric inhibitor of SHP2, SHP099 is a recently identified synthetic small molecule which has demonstrated reduced off-target cytotoxicity and high-target specificity against receptor-tyrosine-kinase-driven cancers in in vitro and in vivo models.1 Here we formulated a local delivery system for this promising chemotherapeutic.